2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Artificial Intelligence (AI), Biological Processes, Apoptosis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Study Population, Human, Animal Model
PAPER

5041 Multi-omics profiling identifies ttk as a therapeutic vulnerability in glucocorticoid-resistant acute lymphoblastic leukemia

Ao Wang, PhD, Yuxuan Liu, PhD2, Fernando Garcia-Marques, PhD3, Milton Merchant4, Pablo Domizi, PhD5, Astraea Jager6, Abel Bermudez7, Abhishek Vallabhbhai Koladiya, PhD8, Calvin Zhu9, Sharon Pitteri10, Kara L. Davis, D.O.11
1 Stanford University, Stanford, California, United States
2 Stanford University, Stanford, California, United States
3 Stanford University, Stanford, California, United States
4 Stanford University, Stanford, California, United States
5 Stanford University, Stanford, California, United States
6 Stanford University, Stanford, California, United States
7 Stanford University, Stanford, California, United States
8 Stanford University, Stanford, California, United States
9 Georgia Institute of Technology, Atlanta, Georgia, United States
10 Stanford University, Stanford, California, United States
11 Stanford University, Stanford, California, United States

Background: Glucocorticoids (GCs) are a cornerstone of acute lymphoblastic leukemia (ALL) therapy. Poor initial response to GCs is a strong predictor of relapse. However, pathways sustaining survival of GC-persistent leukemic cells remain poorly understood, and targeted therapeutic strategies to eliminate these cells are lacking. MYC oncoprotein is a central driver of leukemogenesis and drug resistance. Upon GC stimulation, the glucocorticoid receptor (GR) translocates to the nucleus and represses MYC transcription, an important component of the GC response in ALL. Our previous studies demonstrated elevated MYC expression in GC non-responder patients, consistent with impaired GC-mediated MYC repression. MYC stability is regulated by O-GlcNAcylation at Thr58 by competing with the destabilizing phosphorylation at the same site. Given the challenge of directly targeting MYC, identifying druggable dependencies associated with GC resistance may provide alternative therapeutic strategies. Here, we performed integrated proteomic and transcriptomic profiling of GC-resistant ALL models and identified threonine tyrosine kinase (TTK), a key regulator of the spindle assembly checkpoint, as a candidate therapeutic vulnerability. TTK is targeted by clinical-stage agents currently under investigation in multiple solid tumors. However, its role in GC-resistant ALL has not been explored.

Methods: Dexamethasone (DEX)-resistant derivatives of three B-cell ALL (B-ALL) cell lines were generated through prolonged DEX exposure. Whole-cell lysates from parental and resistant cells were analyzed by label-free quantitative shotgun proteomics, with matched RNA sequencing. TTK dependency was evaluated using the TTK inhibitor BAY-1217389 and shRNA-mediated knockdown in B-ALL and T-ALL cell lines. Protein expression and signaling changes were assessed by western blot and flow cytometry. To evaluate the role of MYC Thr58 regulation in GC resistance, NALM6 cells were engineered to express wild-type MYC or degradation-resistant MYC-T58A.

Results: Integrated proteomic and transcriptomic profiling of DEX-resistant versus parental ALL cells revealed coordinated activation of proliferative and survival-associated pathways. Proteomic analysis demonstrated enrichment of mitotic and spindle assembly checkpoint pathways, with TTK among the upregulated proteins (approximately four-fold increase, p value = 0.043), identifying TTK as a potential therapeutic vulnerability. In parallel, RNA sequencing revealed enrichment of MYC target gene signatures and suppression of apoptotic pathways, suggesting persistent MYC activity contributes to the resistant state. Flow cytometric analysis further demonstrated reduced GR expression in DEX-resistant cells. Pharmacologic inhibition of TTK with BAY-1217389 potently reduced viability of DEX-resistant B-ALL cells (IC50 = 2–5 nM, n = 3 cell lines). Because most T-ALL cell lines are intrinsically GC resistant, we extended these studies to T-ALL models and observed comparable sensitivity to TTK inhibition across both B-ALL and T-ALL cell lines (IC50 = 1–7 nM, n = 4 cell lines).

Expression of the degradation-resistant MYC-T58A mutant rendered otherwise GC-sensitive NALM6 cells completely resistant to DEX, whereas overexpression of wild-type MYC did not. Importantly, BAY-1217389 retained potent activity against MYC-T58A-expressing cells, demonstrating that TTK inhibition remains effective in the setting of MYC-mediated GC resistance. Consistent with these findings, shRNA-mediated depletion of endogenous TTK was associated with reduced MYC protein abundance in both B-ALL and T-ALL cells.

Conclusions: Our findings identify TTK as a previously unrecognized therapeutic vulnerability in pediatric ALL. Although identified through GC-resistant models, TTK inhibition demonstrated potent activity across both GC-sensitive and -resistant B-ALL and T-ALL, including leukemic cells with stabilized MYC. These findings suggest that TTK dependency is maintained in the setting of MYC-mediated GC resistant ALL. Given the longstanding challenge of directly targeting MYC, TTK inhibition may provide an indirect therapeutic strategy for MYC-mediated GC-resistant ALL. In addition, our data identify the reciprocal O-GlcNAcylation and phosphorylation of MYC Thr58 as an important determinant of GC resistance in ALL.

Ao Wang, PhD: No relevant conflicts of interest to declare.